Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Shares of Google parent Alphabet slump after quarterly revenue misses analysts’ expectations, AMD’s data-center revenue ...